Brainsonix develops next-generation focused ultrasound platforms designed for precision, safety, and translational research.
Related Posts
Health
Foods High in Iron: What to Eat and Why It Matters
November 6, 2025
Foods High in Iron: What to Eat and Why It Matters
Blog
This paper described the design and operational framework of a clinically deployable low-intensity focused ultrasound pulsation system, the BrainSonix BX Pulsar 1002. The system was engineered explicitly for human neuromodulation, with an emphasis on calibration accuracy, reproducibility, and built-in safety controls rather than maximal acoustic output. At a time when many ultrasound systems were bespoke laboratory tools, this work articulated what was required for clinical-grade deployment. Key contributions included a single-element transducer architecture with well-characterized focal properties, defined operating envelopes, and real-time monitoring to ensure consistent delivery across sessions and operators. These design principles enabled the transition of focused ultrasound neuromodulation from experimental feasibility to scalable, multi-site clinical research. The BX Pulsar 1002 operationalized these concepts into a turnkey system, supporting standardized protocols and broader adoption across clinical and research settings.
January 6, 2026
This paper described the design and operational framework of a clinically deployable low-intensity focused ultrasound pulsation system, the BrainSonix BX Pulsar 1002. The system was engineered explicitly for human neuromodulation, with an emphasis on calibration accuracy, reproducibility, and built-in safety controls rather than maximal acoustic output. At a time when many ultrasound systems were bespoke laboratory tools, this work articulated what was required for clinical-grade deployment. Key contributions included a single-element transducer architecture with well-characterized focal properties, defined operating envelopes, and real-time monitoring to ensure consistent delivery across sessions and operators. These design principles enabled the transition of focused ultrasound neuromodulation from experimental feasibility to scalable, multi-site clinical research. The BX Pulsar 1002 operationalized these concepts into a turnkey system, supporting standardized protocols and broader adoption across clinical and research settings.
Press
BrainSonix Congratulates Dr. Susan Bookheimer on Her NIH R01 for Alzheimer’s Disease and Mild Cognitive Impairment Research!
January 20, 2026